LogicBio Therapeutics focuses on disease-modifying gene therapies for orphan paediatric diseases by combining gene therapy and editing in a one-time treatment. The company was founded with core platform technologies discovered by Dr Adi Barzel (Tel Aviv University), Dr Leszek Lisowski (Children’s Medical Research Institute, Australia), and Professor Mark Kay (Stanford). Its first platform, GeneRide, uses homologous recombination to enable precise, site-specific transfer of therapeutic genetic material without promoters or nucleases. LogicBio also has access to a library of synthetic, non-pathogenic recombinant AAV vectors developed at Stanford to improve predictability of vector performance in clinical trials. The company has additional science teams working in Tel Aviv. LogicBio intends to use the funds to advance gene therapies targeting orphan paediatric disorders through clinical trials. The company has raised approximately $50M in financing to date. LogicBio Therapeutics develops recombinant adeno-associated virus (rAAV)-mediated gene targeting therapies aimed at inherited diseases, notably hemophilia; its work has been discussed alongside CRISPR gene-editing approaches. The company's LinkedIn lists programs targeting hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Founded in 2014 by Adi Barzel, LogicBio is led by CEO Leszek Lisowski and lists directors including OrbiMed Israel’s Erez Chimovitz and Stanford’s Mark Kay. The startup remains fairly stealth and does not appear to have a public website. According to a regulatory filing, LogicBio has brought in $4 million of a proposed $5.4 million early capital raise. Company descriptions emphasize a proprietary, non-pathogenic AAV vector intended to offer improved efficiency and safety and to be suitable for treating both children and adults.

Total raised

$49M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2017